Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease.

ABSTRACT

Recent studies have reported that patients with von Willebrand disease treated perioperatively with a von Willebrand factor (VWF)/factor VIII (FVIII) concentrate with a ratio of 2.41 (Humate P/Haemate P) often present with VWF and/or FVIII levels outside of prespecified target levels necessary to prevent bleeding. Pharmacokinetic (PK)-guided dosing may resolve this problem. As clinical guidelines increasingly recommend aiming for certain target levels of both VWF and FVIII, application of an integrated population PK model describing both VWF activity (VWFAct) and FVIII levels may improve dosing and quality of care. In total, 695 VWFAct and 894 FVIII level measurements from 118 patients (174 surgeries) who were treated perioperatively with the VWF/FVIII concentrate were used to develop this population PK model using nonlinear mixed-effects modeling. VWFAct and FVIII levels were analyzed simultaneously using a turnover model. The protective effect of VWFAct on FVIII clearance was described with an inhibitory maximum effect function. An average perioperative VWFAct level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours. Clearly, in the presence of VWF, FVIII clearance decreased with a concomitant increase of FVIII half-life, clarifying the higher FVIII levels observed after repetitive dosing with this concentrate. VWFAct and FVIII levels during perioperative treatment were described adequately by this newly developed integrated population PK model. Clinical application of this model may facilitate more accurate targeting of VWFAct and FVIII levels during perioperative treatment with this specific VWF/FVIII concentrate (Humate P/Haemate P).